Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
2.860
-0.060 (-2.05%)
At close: Oct 26, 2026, 4:00 PM EDT
2.840
-0.020 (-0.70%)
After-hours: Oct 26, 2026, 7:30 PM EDT
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%. That makes Entera Bio the 46,675th largest company in the world by revenue and 6,994th in the United States.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
497.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Valneva SE | 163.30M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Oculis Holding AG | 1.45M |
| Neurogene | 925.00K |
ENTX News
- 12 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 13 days ago - Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting - GlobeNewsWire
- 18 days ago - Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting - GlobeNewsWire
- 20 days ago - Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise - GlobeNewsWire
- 4 weeks ago - Guggenheim starts Entera with Buy on N-tab platform potential - TheFly
- 4 weeks ago - Entera Bio initiated with a Buy at Guggenheim - TheFly
- 4 weeks ago - Entera Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Entera Bio initiated with an Outperform at LifeSci Capital - TheFly